Shilpa Commissions Integrated ADC Drug Substance GMP Manufacturing Facility
India-based Shilpa Biologicals has officially commissioned a state-of-the-art antibody–drug conjugate (ADC) GMP manufacturing facility, strategically designed to comply with global regulatory standards, including those set forth by the U.S. FDA and EMA. This facility is now fully operational, with GMP qualification protocols currently in progress. Sridevi Khambhampaty, CEO of Shilpa Biologicals, emphasized that the production…









